Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Brame AL"'
Publikováno v:
Scientific Sessions of the American-Heart-Association (AHA)
E76
E75
E76
E75
Introduction: The peptide apelin acts via G proteins to cause beneficial vasodilation and potent positive inotropy to ameliorate pulmonary arterial hypertension in humans and animal models. Apelin is internalised via β-arrestin. In contrast, with lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::5e29e6b04c5b101d31e23297944673f8
http://hdl.handle.net/10044/1/79718
http://hdl.handle.net/10044/1/79718
Autor:
Yang, P, Kuc, RE, Brame, AL, Dyson, A, Singer, M, Glen, RC, Cheriyan, J, Wilkinson, IB, Davenport, AP, Maguire, JJ
Aims: Apelin is a predicted substrate for ACE2, a novel therapeutic target. Our aim was to demonstrate the endogenous presence of the putative ACE2 product [Pyr(1)]apelin-13(1-12) in human cardiovascular tissues and to confirm it retains significant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7a4f20e376b2145b7cf1872a3df8806
Autor:
Yang P; Department of Medicine, Experimental Medicine and Immunotherapeutics, University of Cambridge Cambridge, UK., Kuc RE; Department of Medicine, Experimental Medicine and Immunotherapeutics, University of Cambridge Cambridge, UK., Brame AL; Department of Medicine, Experimental Medicine and Immunotherapeutics, University of Cambridge Cambridge, UK., Dyson A; Division of Medicine, Bloomsbury Institute of Intensive Care Medicine, University College London London, UK., Singer M; Division of Medicine, Bloomsbury Institute of Intensive Care Medicine, University College London London, UK., Glen RC; Department of Chemistry, Centre for Molecular Informatics, University of CambridgeCambridge, UK; Department of Surgery and Cancer, Biomolecular Medicine, Imperial College LondonLondon, UK., Cheriyan J; Department of Medicine, Experimental Medicine and Immunotherapeutics, University of Cambridge Cambridge, UK., Wilkinson IB; Department of Medicine, Experimental Medicine and Immunotherapeutics, University of Cambridge Cambridge, UK., Davenport AP; Department of Medicine, Experimental Medicine and Immunotherapeutics, University of Cambridge Cambridge, UK., Maguire JJ; Department of Medicine, Experimental Medicine and Immunotherapeutics, University of Cambridge Cambridge, UK.
Publikováno v:
Frontiers in neuroscience [Front Neurosci] 2017 Feb 28; Vol. 11, pp. 92. Date of Electronic Publication: 2017 Feb 28 (Print Publication: 2017).
Autor:
Brame AL; From the Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, UK (A.L.B., J.J.M., P.Y., J.C., I.B.W., A.P.D.); Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK (A.D., M.S.); and Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of. Cambridge, Cambridge, UK (R.T., R.C.G.)., Maguire JJ; From the Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, UK (A.L.B., J.J.M., P.Y., J.C., I.B.W., A.P.D.); Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK (A.D., M.S.); and Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of. Cambridge, Cambridge, UK (R.T., R.C.G.)., Yang P; From the Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, UK (A.L.B., J.J.M., P.Y., J.C., I.B.W., A.P.D.); Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK (A.D., M.S.); and Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of. Cambridge, Cambridge, UK (R.T., R.C.G.)., Dyson A; From the Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, UK (A.L.B., J.J.M., P.Y., J.C., I.B.W., A.P.D.); Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK (A.D., M.S.); and Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of. Cambridge, Cambridge, UK (R.T., R.C.G.)., Torella R; From the Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, UK (A.L.B., J.J.M., P.Y., J.C., I.B.W., A.P.D.); Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK (A.D., M.S.); and Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of. Cambridge, Cambridge, UK (R.T., R.C.G.)., Cheriyan J; From the Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, UK (A.L.B., J.J.M., P.Y., J.C., I.B.W., A.P.D.); Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK (A.D., M.S.); and Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of. Cambridge, Cambridge, UK (R.T., R.C.G.)., Singer M; From the Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, UK (A.L.B., J.J.M., P.Y., J.C., I.B.W., A.P.D.); Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK (A.D., M.S.); and Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of. Cambridge, Cambridge, UK (R.T., R.C.G.)., Glen RC; From the Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, UK (A.L.B., J.J.M., P.Y., J.C., I.B.W., A.P.D.); Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK (A.D., M.S.); and Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of. Cambridge, Cambridge, UK (R.T., R.C.G.)., Wilkinson IB; From the Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, UK (A.L.B., J.J.M., P.Y., J.C., I.B.W., A.P.D.); Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK (A.D., M.S.); and Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of. Cambridge, Cambridge, UK (R.T., R.C.G.)., Davenport AP; From the Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, UK (A.L.B., J.J.M., P.Y., J.C., I.B.W., A.P.D.); Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK (A.D., M.S.); and Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of. Cambridge, Cambridge, UK (R.T., R.C.G.). apd10@medschl.cam.ac.uk.
Publikováno v:
Hypertension (Dallas, Tex. : 1979) [Hypertension] 2015 Apr; Vol. 65 (4), pp. 834-40. Date of Electronic Publication: 2015 Feb 23.